TriangleSMS001 (NCT06693336)
SMS001 trial for Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) (NCT06693336). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged eighteen to eighty with operable non-small-cell lung cancer in specified stage I through IIIA N2 groups. Prior chemotherapy or chest radiation, T3 or T4 tumors, and distant spread exclude participation.
The idea: give SMS001, a new paclitaxel formulation, once during lung surgery. Paclitaxel disrupts structures needed for cell division. Early groups guide dose selection. Researchers assess safety and recurrence. Patients must be candidates for complete tumor removal and lymph-node assessment.
This phase 2 study plans 42 patients. ToLymph sponsors Mayo Clinic in Rochester, the recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.